openPR Logo
Press release

Biosimilar Interleukins Market 2024 - By Analysis, Trend, Future Scope, Demand, Leading Key Players And Industry Growth Forecast Till 2033

02-16-2024 12:05 PM CET | Health & Medicine

Press release from: The Business research company

Biosimilar Interleukins Market

Biosimilar Interleukins Market

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Biosimilar Interleukins Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 39.0%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, increasing patient demand for biosimilars.

The biosimilar interleukins market size is expected to see exponentially grown in the next few years. It will grow to $20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to growing patient population, increased access to healthcare, growing demand for personalized medicine, growing demand for minimally invasive procedures. Major trends in the forecast period include advances in biosimilar technology, targeted immunotherapies, quality control and manufacturing, global collaboration.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Market Segmentation:
The biosimilar interleukins market covered in this report is segmented -
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Major Driver - Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market
The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefits in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to a Johns Hopkins University report published in 2021, autoimmune diseases affected approximately 3% of the population in the United States or approximately 10 million people. Therefore the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

Competitive Landscape:
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sorrento Therapeutics, Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Biogen Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Mylan N.V.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Top Trend - Biogen Launches Tofidence, An Innovative Biologic Treatment
Major companies operating in the biosimilar interleukins market are innovating new products such as Tofidence (tocilizumab-bavi) to increase their profitability in the market.Tofidence is a monoclonal antibody that targets and attaches to interleukin-6 receptors, employed in the treatment of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen, a US-based biotechnology company got approval from the FDA for Tofidence (tocilizumab-bavi) as the first biosimilar to reference Genentech's Actemra (tocilizumab).Tofidence is administered through intravenous infusion and has received approval for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biosimilar Interleukins Market Characteristics
3. Biosimilar Interleukins Market Trends And Strategies
4. Biosimilar Interleukins Market - Macro Economic Scenario
5. Biosimilar Interleukins Market Size And Growth
…..
27. Biosimilar Interleukins Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Interleukins Market 2024 - By Analysis, Trend, Future Scope, Demand, Leading Key Players And Industry Growth Forecast Till 2033 here

News-ID: 3387707 • Views:

More Releases from The Business research company

Event Camera Module Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth
Event Camera Module Market Landscape to 2034: Key Forces Shaping the Next Decade …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Event Camera Module Industry Market Size Be by 2025? The market for event camera modules has experienced swift expansion in the past few years. Expectations are to see it rise from $3.82 billion in 2024 to $4.53 billion in 2025, with a compound annual growth rate
Enterprise Imaging Information Technology (IT) Market Poised to Hit $3.89 Billion by 2029 with Accelerating Growth Trends
Enterprise Imaging Information Technology (IT) Market Poised to Hit $3.89 Billio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Enterprise Imaging Information Technology (IT) Market Size By 2025? The size of the enterprise imaging information technology (IT) market has seen significant expansion in the past few years. Its size is predicted to escalate from $2.10 billion in 2024 to $2.39 billion in 2025, reflecting
Key Trends Reshaping the Electronic Payment Processing Market: Enhancing Transaction Security Through Biometric Authentication Industry Transformation
Key Trends Reshaping the Electronic Payment Processing Market: Enhancing Transac …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Electronic Payment Processing Market Size Growth Forecast: What to Expect by 2025? The market size of electronic payment processing has seen a swift surge in recent years. It's set to expand from $100.73 billion in 2024 to $112.36 billion in 2025, boasting a compound annual growth rate (CAGR) of
Increasing Proliferation Of Internet Of Things (IoT) Devices Fueling The Growth Of The Market Due To Rising Need For Real-Time Data Processing And Smarter Automation: A Key Catalyst Accelerating Edge Artificial Intelligence Accelerator Market Growth in 20
Increasing Proliferation Of Internet Of Things (IoT) Devices Fueling The Growth …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Edge Artificial Intelligence Accelerator Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size of the edge artificial intelligence accelerator has witnessed a significant surge recently. It is projected to expand from $8.28 billion in 2024 to $11.10 billion in 2025, boasting a compound

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of